Subscribe
istock-521307738_pichet_w
pichet_w / iStockphoto.com
22 May 2018Big Pharma

UKIPO issues formal response to Industrial Strategy IP views

The UK Intellectual Property Office (IPO) has published several proposals, including some addressing barriers to growth for IP-rich companies, in response to received views of IP with regard to the government’s Industrial Strategy.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
MSD launches UK hub as government announces industrial strategy
27 November 2017   MSD, known as Merck and Co in the US and Canada, announced plans to launch a life sciences discovery research facility just hours ahead of the UK government’s release of its industrial strategy.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
MSD launches UK hub as government announces industrial strategy
27 November 2017   MSD, known as Merck and Co in the US and Canada, announced plans to launch a life sciences discovery research facility just hours ahead of the UK government’s release of its industrial strategy.

More on this story

Big Pharma
MSD launches UK hub as government announces industrial strategy
27 November 2017   MSD, known as Merck and Co in the US and Canada, announced plans to launch a life sciences discovery research facility just hours ahead of the UK government’s release of its industrial strategy.

More features

Judge denies Intellia bid to throw out suit over $100m Regeneron pact
‘AI curious’ counsel at AZ, Novartis weigh risks and benefits
Trump’s return sparks calls for pro-patent agenda
EOFlow ordered to pay rival $452m over insulin patch trade secrets
Amgen faces pushback over bid to narrow patent scope
LSPN Europe: Navigating the EPO and lessons from the UPC frontline
Paul Hastings reinforces London office with high-tech patent litigator
Gene tech firm fends off injunction in test kit dispute